Empagliflozin/metformin

PBAC's latest decision on Empagliflozin/metformin: Recommended with restriction (2015). Considered for Type 2 diabetes mellitus where metformin alone does not provide adequate glycaemic control. Empagliflozin/metformin fixed dose combination provides a treatment alternative for patients taking concomitant empagliflozin and metformin.

Eligible population

Adults with Type 2 diabetes mellitus with insufficient glycaemic control (HbA1c >7% or blood glucose >10 mmol/L in >20% of tests over 2 weeks) despite treatment with metformin, for dual therapy, triple therapy with a sulfonylurea, or add-on combination with insulin.

Therapy area

Endocrinology

Line of therapy

Any

Evidence base

Cost-minimisation

Primary endpoint

Cost-minimisation

Key trials

1276.5, 1276.6, 1276.7, 1276.8, 1276.23, 1276.24, 1276.9, 1245.10, 1245.23, 1245.31

Comparator

co-administered individual components (empagliflozin and metformin immediate release)

Economic model

Cost-minimisation

ICER note

Cost-minimisation analysis; no ICER calculated by design.

Similar precedents

• Empagliflozin
  similarity 0.82
• Empagliflozin, empagliflozin with metformin, linagliptin, linagliptin with metformin
  similarity 0.81
• Metformin and sitagliptin
  similarity 0.77
• Empagliflozin with linagliptin
  similarity 0.77
• Ertugliflozin
  similarity 0.76
• Linagliptin with metformin hydrochloride
  similarity 0.75